Efficacy, Safety, and Tolerability of Efgartigimod in Patients With Generalized Myasthenia Gravis: Analysis of the Phase 3 ADAPT Study (4520)-Reference-Cited by-同舟云学术

Efficacy, Safety, and Tolerability of Efgartigimod in Patients With Generalized Myasthenia Gravis: Analysis of the Phase 3 ADAPT Study (4520)

Published:2021-04-13 Issue:15_supplement Volume:96 Page:
ISSN:0028-3878
Container-title:Neurology
language:en
Short-container-title:Neurology

Author:

Howard James¹,Bril Vera²,Vu Tuan³,Karam Chafic⁴,Peric Stojan⁵,Murai Hiroyuki⁶,Guglietta Antonio⁷,Ulrichts Peter⁷,Vangeneugden Tony⁷,Utsugisawa Kimiaki⁸,Verschuuren Jan⁹,Mantegazza Renato¹⁰

Affiliation:

1. The University of North Carolina, Dept of Neurology, CB 7025

2. Toronto General Hospital

3. University of South Florida

4. Penn Neuroscience Center, Hospital of the University of Pennsylvania

5. Neurology, University of Belgrade School of Medicine

6. Neurology, International University of Health and Welfare

7. argenx

8. Neurology, Hanamaki General Hospital

9. Leiden University Medical Center

10. Neuroimmunology and Neuromuscular Diseases, Fondazione Istituto Neurologico Carlo Besta

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical)

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Several more myasthenia gravis therapy options now available;Drugs & Therapy Perspectives;2024-07-20

2. Commentary: Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis;Frontiers in Immunology;2024-05-17

3. Case report: A highly active refractory myasthenia gravis with treatment of telitacicept combined with efgartigimod;Frontiers in Immunology;2024-05-10

4. Exploring the depths of IgG4: insights into autoimmunity and novel treatments;Frontiers in Immunology;2024-04-18

5. The intricate dance of non-coding RNAs in myasthenia gravis pathogenesis and treatment;Frontiers in Immunology;2024-03-27